natals, Inc. – Trademark Portfolio
Entity Type: 03
natals, Inc. holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 14 trademarks are registered and 2 are pending. Notable registered marks include RITUAL, HYACERA, BIOSERIES, SYNBIOTIC+, and NATALBIOTIC. The owner is based in Los Angeles, CA.
6421 Drexel Avenue
Los Angeles, CA 90048
Showing of trademarks Trademarks
Trademark Classifications
natals, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does natals, Inc. have?
natals, Inc. has 26 U.S. trademarks filed with the USPTO. Of these, 14 registered, 2 pending, 9 abandoned, 1 cancelled.
What trademark classes does natals, Inc. file in?
natals, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are natals, Inc.'s most well-known trademarks?
natals, Inc.'s registered trademark portfolio includes well-known marks such as RITUAL, HYACERA, BIOSERIES, SYNBIOTIC+, and NATALBIOTIC. These are among 14 currently registered trademarks in the portfolio.
What is natals, Inc.'s trademark registration success rate?
natals, Inc. has a 58% trademark registration rate, with 14 out of 24 resolved applications resulting in successful registration. Currently, 2 applications are pending review.